Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
Hospitalization
Serious outcomes
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for PVP-I  COVID-19 treatment studies for Povidone-Iod..  C19 studies: Povidone-Iod..  Povidone-Iod..   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption
Outcomes in COVID-19 povidone-iodine studies
00.250.50.7511.251.51.752+Mohamed (RCT)86%0.14 [0.01-2.21]viral+0/53/5Improvement, RR [CI]TreatmentControlChoudhury (RCT)88%0.12 [0.03-0.50]death2/30317/303Guenezan (RCT)63%0.37 [0.06-1.63]viral load12 (n)12 (n)Elzein (DB RCT)89%0.11 [0.01-1.00]viral load25 (n)9 (n)Arefin (RCT)79%0.21 [0.08-0.54]viral+4/2719/27Baxter (RCT)65%0.35 [0.01-8.27]hosp.0/371/42OT​1Tau​2 = 0.00; I​2 = 0.0%Early treatment81%0.19 [0.10-0.37]6/40940/39881% improvementSeet (CLUS. RCT)45%0.55 [0.38-0.80]severe case42/73564/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP45%0.55 [0.38-0.80]42/73564/61945% improvementAll studies71%0.29 [0.16-0.54]48/1,144104/1,01771% improvement7 povidone-iodine COVID-19 studiesc19pvpi.com Oct 15, 20211 OT: comparison with other treatmentTau​2 = 0.20; I​2 = 34.1%; Z = 3.97Effect extraction pre-specifiedFavors povidone-iodineFavors control 00.250.50.7511.251.51.752+Choudhury (RCT)88%0.12 [0.03-0.50]2/30317/303Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment88%0.12 [0.03-0.50]2/30317/30388% improvementAll studies88%0.12 [0.03-0.50]2/30317/30388% improvement1 povidone-iodine COVID-19 mortality resultc19pvpi.com Oct 15, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.88Favors povidone-iodineFavors control 00.250.50.7511.251.51.752+Choudhury (RCT)84%0.16 [0.09-0.28]hosp.12/30377/303Improvement, RR [CI]TreatmentControlBaxter (RCT)65%0.35 [0.01-8.27]hosp.0/371/42OT​1Tau​2 = 0.00; I​2 = 0.0%Early treatment84%0.16 [0.09-0.29]12/34078/34584% improvementAll studies84%0.16 [0.09-0.29]12/34078/34584% improvement2 povidone-iodine COVID-19 hospitalization resultsc19pvpi.com Oct 15, 20211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 6.22Favors povidone-iodineFavors control 00.250.50.7511.251.51.752+Choudhury (RCT)88%0.12 [0.03-0.50]death2/30317/303Improvement, RR [CI]TreatmentControlBaxter (RCT)65%0.35 [0.01-8.27]hosp.0/371/42OT​1Tau​2 = 0.00; I​2 = 0.0%Early treatment86%0.14 [0.04-0.53]2/34018/34586% improvementSeet (CLUS. RCT)45%0.55 [0.38-0.80]severe case42/73564/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP45%0.55 [0.38-0.80]42/73564/61945% improvementAll studies67%0.33 [0.11-1.01]44/1,07582/96467% improvement3 povidone-iodine COVID-19 serious outcomesc19pvpi.com Oct 15, 20211 OT: comparison with other treatmentTau​2 = 0.52; I​2 = 51.4%; Z = 1.95Effect extraction pre-specifiedFavors povidone-iodineFavors control 00.250.50.7511.251.51.752+Seet (CLUS. RCT)31%0.69 [0.37-1.01]338/735433/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP31%0.69 [0.37-1.01]338/735433/61931% improvementAll studies31%0.69 [0.63-0.76]338/735433/61931% improvement1 povidone-iodine COVID-19 case resultc19pvpi.com Oct 15, 20211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 7.77Favors povidone-iodineFavors control 00.250.50.7511.251.51.752+Mohamed (RCT)86%0.14 [0.01-2.21]viral+0/53/5Improvement, RR [CI]TreatmentControlChoudhury (RCT)96%0.04 [0.02-0.07]viral+8/303213/303Guenezan (RCT)63%0.37 [0.06-1.63]viral load12 (n)12 (n)Elzein (DB RCT)89%0.11 [0.01-1.00]viral load25 (n)9 (n)Arefin (RCT)79%0.21 [0.08-0.54]viral+4/2719/27Tau​2 = 0.87; I​2 = 67.0%Early treatment88%0.12 [0.04-0.36]12/372235/35688% improvementAll studies88%0.12 [0.04-0.36]12/372235/35688% improvement5 povidone-iodine COVID-19 viral clearance resultsc19pvpi.com Oct 15, 2021Tau​2 = 0.87; I​2 = 67.0%; Z = 3.86Favors povidone-iodineFavors control 00.250.50.7511.251.51.752+Mohamed (RCT)86%0.14 [0.01-2.21]viral+0/53/5Improvement, RR [CI]TreatmentControlChoudhury (RCT)88%0.12 [0.03-0.50]death2/30317/303Guenezan (RCT)63%0.37 [0.06-1.63]viral load12 (n)12 (n)Elzein (DB RCT)89%0.11 [0.01-1.00]viral load25 (n)9 (n)Arefin (RCT)79%0.21 [0.08-0.54]viral+4/2719/27Baxter (RCT)65%0.35 [0.01-8.27]hosp.0/371/42OT​1Tau​2 = 0.00; I​2 = 0.0%Early treatment81%0.19 [0.10-0.37]6/40940/39881% improvementSeet (CLUS. RCT)45%0.55 [0.38-0.80]severe case42/73564/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP45%0.55 [0.38-0.80]42/73564/61945% improvementAll studies71%0.29 [0.16-0.54]48/1,144104/1,01771% improvement7 povidone-iodine COVID-19 Randomized Controlled Trialsc19pvpi.com Oct 15, 20211 OT: comparison with other treatmentTau​2 = 0.20; I​2 = 34.1%; Z = 3.97Effect extraction pre-specifiedFavors povidone-iodineFavors control 00.250.50.7511.251.51.752+Choudhury (RCT)88%0.12 [0.03-0.50]2/30317/303Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment88%0.12 [0.03-0.50]2/30317/30388% improvementAll studies88%0.12 [0.03-0.50]2/30317/30388% improvement1 povidone-iodine COVID-19 RCT mortality resultc19pvpi.com Oct 15, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.88Favors povidone-iodineFavors control 00.250.50.7511.251.51.752+Choudhury (RCT)88%0.12 [0.03-0.50]death2/30317/303Improvement, RR [CI]TreatmentControlGuenezan (RCT)63%0.37 [0.06-1.63]viral load12 (n)12 (n)Elzein (DB RCT)89%0.11 [0.01-1.00]viral load25 (n)9 (n)Arefin (RCT)79%0.21 [0.08-0.54]viral+4/2719/27Tau​2 = 0.00; I​2 = 0.0%Early treatment81%0.19 [0.10-0.38]6/36736/35181% improvementSeet (CLUS. RCT)45%0.55 [0.38-0.80]severe case42/73564/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP45%0.55 [0.38-0.80]42/73564/61945% improvementAll studies72%0.28 [0.14-0.58]48/1,102100/97072% improvement5 povidone-iodine COVID-19 peer reviewed trialsc19pvpi.com Oct 15, 20211 OT: comparison with other treatmentTau​2 = 0.32; I​2 = 52.8%; Z = 3.43Effect extraction pre-specifiedFavors povidone-iodineFavors control 00.250.50.7511.251.51.752+Mohamed (RCT)86%0.14 [0.01-2.21]viral+0/53/5Improvement, RR [CI]TreatmentControlChoudhury (RCT)88%0.12 [0.03-0.50]death2/30317/303Choudhury (RCT)84%0.16 [0.09-0.28]hosp.12/30377/303Choudhury (RCT)96%0.04 [0.02-0.07]viral+8/303213/303Guenezan (RCT)63%0.37 [0.06-1.63]viral load12 (n)12 (n)Elzein (DB RCT)89%0.11 [0.01-1.00]viral load25 (n)9 (n)Arefin (RCT)79%0.21 [0.08-0.54]viral+4/2719/27Arefin (RCT)89%0.11 [0.03-0.41]viral+2/2719/27Arefin (RCT)53%0.47 [0.26-0.85]viral+9/2719/27Arefin (RCT)80%0.20 [0.09-0.44]viral+5/2725/27Arefin (RCT)64%0.36 [0.21-0.62]viral+9/2725/27Arefin (RCT)74%0.26 [0.19-0.37]viral+29/13544/54Baxter (RCT)65%0.35 [0.01-8.27]hosp.0/371/42OT​1Baxter (RCT)79%0.21 [0.01-4.24]hosp./ER0/372/42OT​1Baxter (RCT)56%0.44 [0.20-0.94]no recov.6/2518/33OT​1Seet (CLUS. RCT)45%0.55 [0.38-0.80]severe case42/73564/619OT​1Seet (CLUS. RCT)31%0.69 [0.37-1.01]cases338/735433/619OT​1povidone-iodine COVID-19 outcomesc19pvpi.com Oct 15, 2021Favors povidone-iodineFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit